Drug intelligence / Profile preview

LRP-666

Development stage: Preclinical
Lead developer: London Research & Pharmaceuticals
Modality: Small Molecules

Overview

LRP-666 is a small molecule therapeutic candidate currently in the early preclinical stage of development by London Research & Pharmaceuticals. The drug is being investigated for its potential in treating a range of conditions, including chronic pain, inflammatory disorders, post-traumatic stress disorder (PTSD), and anxiety. While the specific molecular target and mechanism of action have not been publicly disclosed, the asset is part of a pipeline focused on addressing significant unmet needs in neurology and immunology.

Other names: LRP-666LRP666LRP 666

Beyond the preview

Go deeper on LRP-666.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LRP-666.

Explore the full profile